DACC in the Prevention of Surgical Site Infection (DRESSINg)

  • Research type

    Research Study

  • Full title

    A randomised controlled trial to assess the clinical and cost effectiveness of Dialkylcarbamoylchloride (DACC) coated post-operative dressings versus standard care in the prevention of Surgical Site Infection in clean or clean-contaminated, vascular surgery.

  • IRAS ID

    215973

  • Contact name

    James Illingworth

  • Contact email

    james.illingworth@hey.nhs.uk

  • Sponsor organisation

    Hull and East Yorkshire Hospitals NHS Trust, R&D Department

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    Surgical site infections occur in around 5% of patients and have a significant impact on patient morbidity and mortality. They have subsequent consequences on healthcare services in terms of prolonged hospital stays, repeated treatments and increased time dedicated by health professionals. Within vascular surgery, surgical site infection has been reported as high as 20%. With a growing number of multi-drug resistant bacteria, it is imperative for research to focus on novel methods of preventing and treating infection.
    Dialkylcarbamoylchloride (DACC) coated dressings are a relatively new wound dressings that work by binding bacteria and removing them from the wound bed when the dressing is removed. Early evidence suggests that this reduced the rate of surgical site infection.
    We aim to assess the clinical and cost effectiveness of post-operative wound dressing with DACC-coated dressings vs conventional dressings in clean or clean contaminated vascular surgery.

  • REC name

    London - Harrow Research Ethics Committee

  • REC reference

    16/LO/2135

  • Date of REC Opinion

    25 Nov 2016

  • REC opinion

    Favourable Opinion